To include your compound in the COVID-19 Resource Center, submit it here.

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Regulatory milestones

Amgen Inc. (NASDAQ:AMGN) was off $0.63 to $55.05 on a newsy Friday. The European Commission approved Xgeva denosumab to prevent skeletal-related events in adults with bone metastases from solid tumors.

Meanwhile, the company resolved U.S. patent litigation with Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), which admitted that its Neutroval (XM02) infringes two U.S. patents covering Amgen's Neupogen filgrastim and agreed not to sell its biologic in the U.S. until after November 2013.

Teva received a complete response letter last year for a BLA for Neutroval; the product was approved in 2008 in Europe as a biosimilar version of Neupogen. Teva was off $1.50 to $47.97 for the week.

Separately, Micromet Inc. (NASDAQ:MITI) gained $0.53 to $6.29 last week after partnering with Amgen to

Read the full 1206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE